The NHS Will Not Be Fixed in This Parliament — What Does That Mean for Your Commercial Strategy?

Is the Government Funding the Change It Is Asking For?

The government's structural logic is sound. But structural reform is not the same as capacity. NHS spending will grow by 2.8% in real terms annually between 2025 and 2029. The historic average required to maintain a stable service is 3.7%. The NHS 10-Year Plan commits to neighbourhood health, prevention, community-based care and digital transformation. The funding flowing into them right now, in the financial year you are trying to close, is far more constrained than the policy language suggests.

Knowing the difference between where policy rhetoric leads and where commissioning budgets actually follow is not a minor operational detail. It is the foundation of a market access strategy that works.

Are NHS Ways of Working the Real Constraint?

The NHS is not a passive victim of underfunding. It is the largest employer in England, with 1.5 million staff, and an institution that has absorbed decades of reform mandates without consistently changing how it operates at the front line.

The Further Faster 20 programme deployed specialist teams into the 20 NHS trusts with the highest economic inactivity. Over 12 months, waiting lists in those trusts fell three times faster than the national average, and more than five times faster for working-age adults. The resources were broadly the same. The ways of working changed.

Online appointment adoption across general practice varies from 33.5% at the most digitally progressive practices to effectively zero at others — with no obvious correlation to resource or population profile. Over a million GP appointments a month go unattended without cancellation: the equivalent of over 2,300 full-time GP salaries lost annually to non-attendance.

The best-performing NHS systems are not the best-funded. They are the ones with the clearest leadership, the strongest clinical engagement, and the least institutional resistance to doing things differently. Identifying those systems and building your early adopter strategy around them — rather than around geography or population size — is one of the highest-value things a market access team can do.

Is Prevention a Realistic Ask Without Structural Support?

Long-term conditions affect around 15 million people in England. They account for 70% of acute and primary care budgets, 70% of hospital bed days and 50% of all GP appointments. Many of those conditions are driven by factors that are structurally shaped as much as they are individually chosen — food environments, sedentary work, housing quality, financial stress.

But the data is clear that the people most at risk are the least likely to be reached by the interventions that exist. The gym boom has not reduced obesity. The NHS Diabetes Prevention Programme works well for people who engage with it. Smoking rates in the most deprived communities remain nearly double those in the least deprived, despite twenty years of national progress.

The Core20PLUS5 framework is not a compliance exercise. It is a signal about where NHS decision-makers believe they have both the greatest unmet need and the greatest obligation to spend.

Is the Industry Making It Easy Enough?

The life sciences industry has a consistent habit of presenting innovation as the solution to NHS capacity pressures while designing products and commercial models that place additional demands on a workforce already at its limit. Every medicine that requires specialist initiation, hospital-based administration, complex monitoring or multi-step pathway management adds to the burden of a system that has 100,000 unfilled posts, 7.25 million people on waiting lists and bed occupancy consistently above 90%.

From April 2026, NICE's technology appraisal process expands to cover medical devices and diagnostics — creating for the first time a mandated funding pathway for medtech that mirrors the one medicines have had for twenty-five years. The products that will gain ground are not necessarily the ones with the strongest clinical data packages. They are the ones whose evidence is accompanied by a credible, quantified answer to the question every commissioner will ask: does this free up clinical time or consume it? Released nurse hours, avoided A&E attendances, reduced outpatient follow-up, earlier community-based diagnosis — these are not supplementary commercial arguments. In the current NHS environment, they are the primary ones.

So What Is the Commercially Intelligent Response?

Not waiting for the system to sort itself out. It will not — quickly, and not on a timescale that maps onto most commercial planning horizons. The companies that navigate the next five years well in the NHS will not be the ones with the largest field forces or the most complete clinical dossiers. They will be the ones that understood the environment clearly, positioned their products as solutions to the pressures commissioners are actually facing, and built the commercial infrastructure to deliver on that positioning at the point of care.